Human plasma quantification of droperidol and ondansetron used in preventing postoperative nausea and vomiting with a LC/ESI/MS/MS method

An analytical method based upon liquid chromatography coupled to ion trap mass spectrometry (MS) detection with electrospray ionization interface has been developed for the simultaneous identification and quantification of droperidol and ondansetron in human plasma. The two drugs were isolated from 0.5mL of plasma using a basic liquid–liquid extraction with diethyl ether/heptane (90/10, v/v) and tropisetron and haloperidol as internal standards, with satisfactory extraction recoveries. They were separated on a 5-μm C18 Highpurity column (150mm×2.1mm I.D.) maintained at 30°C. The elution was achieved isocratically with a mobile phase of 2mM HCOONH4 pH 3.8 buffer/acetonitrile (60/40, v/v) at a flow rate of 200μL/min. Data were collected either in full-scan MS mode at m/z 100–450 or in full-scan MS–MS mode, selecting the [M+H] + ion at m/z=294.0 for ondansetron, m/z=285.2 for tropisetron, m/z=380.0 for droperidol and m/z=376.0 for haloperidol. The most intense daughter ion of ondansetron (m/z=212.0) and droperidol (m/z=194.0) were used for quantification. Retention times for tropisetron, ondansetron, droperidol and haloperidol were 2.50, 2.61, 3.10 and 4.68min, respectively. Calibration curves were linear for both compounds in the 0.50–500ng/mL range. The limits of detection and quantification were 0.10ng/mL and 0.50ng/mL, respectively. The intra- and inter-assay precisions were lower than 6.4% and intra- and inter-assay recoveries were in the 97.6–101.9% range for the three 3, 30 and 300ng/mL concentrations. This method allows simultaneous and rapid measurement of droperidol and ondansetron, which are frequently co-administrated for the prevention of postoperative nausea and vomiting.